SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001104659-20-132044
Filing Date
2020-12-03
Accepted
2020-12-03 17:08:46
Documents
3
Group Members
AESCAP VENTURE MANAGEMENT B.V.JOHAN GERHARD BOSMANMICHIEL ALEXANDER DE HAANPATRICK JOHAN HENDRIK KROL

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D tm2037640d1_sc13d.htm SC 13D 97626
2 EXHIBIT 99.1 tm2037640d1_ex99-1.htm EX-99.1 7583
3 EXHIBIT 99.2 tm2037640d1_ex99-2.htm EX-99.2 28191
  Complete submission text file 0001104659-20-132044.txt   135212
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Subject) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-89626 | Film No.: 201367637
SIC: 2834 Pharmaceutical Preparations

Mailing Address BARBARA STROZZILAAN 101 AMSTERDAM P7 1083 HN
Business Address BARBARA STROZZILAAN 101 AMSTERDAM P7 1083 HN 31 20 570 29 45
Cooperatieve AESCAP Venture I U.A. (Filed by) CIK: 0001834629 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SC 13D